Today's Pre-Open Stock Movers

INmune Bio, Inc. (NASDAQ: INMB) 32.5% HIGHER; announced today that results from a Phase 1b study demonstrate that XPro1595, an investigational dominant-negative protein that neutralizes soluble TNF, decreases biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid (CSF) and MRI, in patients with Alzheimer’s disease (AD). The data suggest that decreasing neuroinflammation results in significant improvements in biomarkers of neurodegeneration and synaptic function.

Oncocyte Corporation (NYSE: OCX) 16.7% HIGHER; announced that it has entered into definitive agreements with its two largest institutional investors to purchase approximately $25 million of Oncocytes common shares in a registered offering priced at $3.424 per share (at market), which was the average of the last five closing prices.

Marathon Patent Group, Inc. (NASDAQ: MARA) 13.7% LOWER; falls on bitcoin weakness

Riot Blockchain, Inc. (NASDAQ: RIOT) 11.9% LOWER; falls on bitcoin weakness

Kodak (NYSE: KODK) 9% HIGHER; announces a partnership with Pigment.inc B.V Europe to distribute Kodak’s KODACOLOR RDTG Series Direct to Garment (DTG) inks.

color:#333333;background:white">Diebold (NYSE: DBD) 6.8% HIGHER color:#333333;background:white">; JPMorgan upgraded color:#333333;background:white">from Neutral to Overweight with a price target of $16.00 (from $10.00).

OncoSec Medical Incorporated (NASDAQ: ONCS) 5.9% LOWER; Intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering will be offered by OncoSec.

Fastly Inc. (NYSE: FSLY) 5.4% HIGHER; Oppenheimer upgraded from Perform to Outperform with a price target of $125.00.

Maxar Technologies Ltd (NYSE: MAXR) 4.3% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $55.00 (from $30.00).

Tellurian (NASDAQ: TELL) 4% HIGHER; Wolfe Research upgraded from Peerperform to Outperform with a price target of $5.00.

Orchid Island Capital, Inc. (NYSE: ORC) 3.8% LOWER; announced today that it plans to make a public offering of 7,600,000 shares of its common stock. The Company also expects to grant the underwriter an option to purchase up to an additional 1,140,000 shares of common stock. J.P. Morgan will serve as sole bookrunning manager for the offering.

21Vianet Group, Inc. (Nasdaq: VNET) 3.6% LOWER; announced a proposed offering (the Notes Offering) of US$525 million in aggregate principal amount of convertible senior notes due 2026 (the Notes) subject to market conditions and other factors. The Company intends to grant the initial purchasers in the Notes Offering a 13-day option to purchase up to an additional US$75 million in aggregate principal amount of the Notes. The Company plans to use the net proceeds from the Notes Offering for expanding data center infrastructure, repaying the Companys outstanding senior notes due 2021 and other general corporate purposes.

Plexus Corp (NASDAQ: PLXS) 3.3% HIGHER; reported Q1 EPS of $1.23, $0.14 better than the analyst estimate of $1.09. Revenue for the quarter came in at $830.36 million versus the consensus estimate of $832.12 million. Plexus Corp sees Q2 2021 EPS of $1.02-$1.17, versus the consensus of $0.99. Plexus Corp sees Q2 2021 revenue of $860-900 million, versus the consensus of $834.57 million.

Alcoa (NYSE: AA) 2.7% LOWER; reported Q4 EPS of $0.26, $0.15 better than the analyst estimate of $0.11. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.35 billion.

You May Also Be Interested In

• Biogen (BIIB) tops earnings expectations but revenue falls short
• JPM sees risk of further negative earnings revisions for Tesla (TSLA)
• JPMorgan First Take on Biogen (BIIB)